In a groundbreaking move, the Trump administration has announced new agreements with Novo Nordisk and Eli Lilly to significantly reduce the cost of GLP-1 medications for American patients, including those on Medicare. With prices set to drop dramatically, millions will soon benefit from affordable access to essential treatments.
In a groundbreaking move, President Trump has negotiated significant price reductions for popular weight loss medications, bringing costs down to as low as $50 per month for eligible patients. Find out how these changes will affect access to essential treatments!
In a groundbreaking move, President Trump announces deals with Eli Lilly and Novo Nordisk to reduce obesity drug prices, making treatments more accessible for millions of Americans. Medicare coverage for GLP-1 drugs starts in 2026, changing the landscape of obesity treatment.
Two biotech companies are developing groundbreaking gene therapies that could lead to a single injection for weight loss and blood sugar control. Initial tests show promising results in mice, with human trials on the horizon.
In a bold move, Pfizer has filed a lawsuit against Novo Nordisk and Metsera, claiming their merger violates antitrust laws and threatens competition in the obesity drug market.
As demand for weight loss and diabetes drugs surges, Eli Lilly and Novo Nordisk dominate the market. Discover the challenges, competition, and future of this booming industry.
A recent Gallup survey reveals a rapid increase in the use of injectable obesity treatments, correlating with a drop in obesity rates among U.S. adults. Discover the implications and future of these groundbreaking medications!
Pfizer is making headlines with its $7.3 billion acquisition of Metsera, a weight loss drugmaker, as it aims to capture a share of the booming obesity drug market. This deal highlights the growing demand for innovative obesity treatments and Pfizer's strategic pivot following setbacks in its own drug pipeline.
Lilly's new oral pill, Orforglipron, has shown promising results in reducing weight and improving blood sugar levels in diabetes patients. With nearly 4% rise in shares, the drug is on track for FDA approval.
A groundbreaking study shows that bariatric surgery leads to five times more weight loss than GLP-1 drugs like semaglutide. Discover why surgery remains the gold standard in obesity treatment.
